Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLKL | Q8NB16 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 4/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | NCOA3 | Q9Y6Q9 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | NCOA1 | Q15788 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21602569 | 0.90 | MLKL (0.68) | MLKLTSHRMAPK1HTTUSP2 | |
| SCHEMBL20489190 | 0.88 | TSHR (0.61) | MLKLTSHRMAPK1HTTUSP2 | |
| SCHEMBL20489178 | 0.85 | MLKL (0.63) | MLKLTSHRMAPK1HTTUSP2 | |
| SCHEMBL21602480 | 0.84 | MLKL (0.77) | MLKLTSHRMAPK1HTTUSP2 | |
| SCHEMBL21602541 | 0.84 | TSHR (0.57) | MLKLTSHRMAPK1HTTUSP2 | |
| SCHEMBL21602576 | 0.83 | MLKL (0.60) | MLKLTSHRMAPK1USP2L3MBTL1 | |
| SCHEMBL21602606 | 0.82 | MLKL (0.58) | MLKLMAPK1L3MBTL1CYP2C19ALDH1A1 | |
| SCHEMBL21602440 | 0.82 | MLKL (0.59) | MLKLTSHRMAPK1HTTUSP2 | |
| SCHEMBL20488494 | 0.82 | MLKL (0.49) | MLKLTSHRMAPK1HTTL3MBTL1 | |
| SCHEMBL21602443 | 0.82 | MLKL (0.49) | MLKLTSHRMAPK1HTTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3612223-B1 | TREATING MALE SENESCENCE | NAT INSTITUTE OF BIOLOGICAL SCIENCES BEIJING (CN) | 2024-07-31 | — | — | EP | claimed |
| CN-110769853-B | Treatment of male aging | 北京生命科学研究所 | 2022-06-03 | — | — | CN | claimed |
| US-11090307-B2 | Treating male senescence | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2021-08-17 | — | — | US | claimed |
| CN-110769853-A | Treatment of male aging | 北京生命科学研究所 | 2020-02-07 | — | — | CN | claimed |
| EP-3612223-B1 | TREATING MALE SENESCENCE | NAT INSTITUTE OF BIOLOGICAL SCIENCES BEIJING (CN) | 2024-07-31 | — | — | EP | disclosed |
| CN-117320754-A | Prostatitis treatment | 北京生命科学研究所 | 2023-12-29 | — | — | CN | disclosed |
| US-11666577-B2 | MLKL inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2023-06-06 | — | — | US | disclosed |
| US-11666577-B2 | MLKL inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2023-06-06 | — | — | US | disclosed |
| US-11666577-B2 | MLKL inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2023-06-06 | — | — | US | disclosed |
| CN-110573509-B | MLKL inhibitors | 北京生命科学研究所 | 2023-05-26 | — | — | CN | disclosed |
| US-20220288077-A1 | PROSTATITIS TREATMENT | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES (CN) | 2022-09-15 | — | — | US | disclosed |
| EP-4017535-A1 | PROSTATITIS TREATMENT | National Institute Of Biological Sciences, Beijing (CN) | 2022-06-29 | — | — | EP | disclosed |
| CN-110769853-B | Treatment of male aging | 北京生命科学研究所 | 2022-06-03 | — | — | CN | disclosed |
| US-11090307-B2 | Treating male senescence | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2021-08-17 | — | — | US | disclosed |
| US-11090307-B2 | Treating male senescence | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2021-08-17 | — | — | US | disclosed |
| US-20200046714-A1 | Treating Male Senescence | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2020-02-13 | — | — | US | disclosed |
| CN-110769853-A | Treatment of male aging | 北京生命科学研究所 | 2020-02-07 | — | — | CN | disclosed |
| WO-2019242576-A1 | TREATING DEMYELINATING DISEASE | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2019-12-26 | — | — | WO | disclosed |
| CN-110573509-A | MLKL inhibitors | 北京生命科学研究所 | 2019-12-13 | — | — | CN | disclosed |
| WO-2018157800-A1 | MLKL INHIBITORS | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2018-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11090307-B2 | Treating male senescence | RIPK3, RIPK1, MLKL | MLKL 3/4885TSHR 4353/4885MAPK1 248/4885 |
| US-20200046714-A1 | Treating Male Senescence | RIPK3, RIPK1, MLKL | MLKL 3/4885TSHR 4353/4885MAPK1 248/4885 |
| US-11666577-B2 | MLKL inhibitors | MLKL, CMKLR1, PCSK9 | MLKL 1/4885TSHR 4699/4885MAPK1 756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.